Abstract
Vitiligo is an acquired skin disorder caused by the disappearance of pigment cells from the epidermis that gives rise to well defined white patches which are often symmetrically distributed. The lack of melanin pigment makes the lesional skin more sensitive to sunburn.
Vitiligo can be cosmetically disfiguring and it is a stigmatizing condition, leading to serious psychologic problems in daily life. It occurs worldwide in about 0.5% of the population and it occurs as frequently in males as it does in females. The cause is unknown, but might involve genetic factors, autoimmunity, neurologic factors, toxic metabolites, and lack of melanocyte growth factors. Since a causative (gene) treatment is not (yet) available, current modalities are directed towards stopping progression and to achieving repigmentation in order to repair the morphology and functional deficiencies of the depigmented skin areas.
Many treatments have been used for some time; however; there are some new developments: narrowband ultraviolet (UV) B (311nm) therapy, the combination of corticosteroid cream + UVA therapy, and the transplantation of autologous pigment cells in various modalities. In widespread vitiligo, residual pigment can be removed by depigmentation agents. Sunscreens, camouflage products, and good guidance may help the patient cope better with the disease.
Similar content being viewed by others
References
Lerner A. Vitiligo. J Invest Dermatol 1959; 32: 285–310
Bhatia P.S., Mohan L., Pandley N., et al. Genetic nature of vitiligo. J Dermatol Sci 1992; 4: 180–184
Schallreuter K.U., Lemke R., Brandt O., et al. Vitiligo and other diseases: coexistence or true association? Hamburg study on 321 patients. Dermatology 1994; 188: 269–275
Kim S.M., Chung H.S., Hann S.K. The genetics of vitiligo in Korean patients. Int J Dermatol 1998; 38: 908–910
Mohr J. Vitiligo in a pair of monoovular twins. Acta Genet Stat Med 2: 1951; 252–255
Siemens H.W. Die zwillingspathologie der Vitiligo. Acta Genet Med Gemellol (Roma) 1953; 2: 118–124
Butterworth T., Strean L.P. Clinical genodermatology. Baltimore, MD: Williams and Wilkins, 1962: 4–6
Lerner A.B.. Vitiligo. In: Dennis R.L., Dobson J., McGuire I. Clinical dermatology. Hagerstown: Harper and Row, 1977. Vol. 2
Salamon T., Hadziselimovic R., Hallepovic E. Zur Frage der Erblichkeit der Vitiligo. Hautarzt 1989; 40: 141–145
Majumder P.P., Das D.K., Li C.C. A genetic model for vitligo. Am J Hum Gen 1988; 43: 119–125
Nath S.K., Majumder P.P., Nordlund J.J. Genetic epidemiology of vitiligo: multilocus recessivity crossvalidated. Am J Hum Genet 1994; 55: 981–990
Majumder P.P., Nordlund J.J., Nath S.K. Pattern of familial aggregation of vitiligo. Arch Dermatol 1993; 129: 994–998
Hafez M., Sharaf L., El-Nabi S.M.A. The genetics of vitiligo. Acta Dermatol Venereol (Stockh) 1983; 63: 249–251
Ando I., Chi H.I., Nakagawa H., et al. Difference in clinical features and HLA antigens between familial and non-familial vitiligo of non-segmental type. Br J Dermatol 1993; 129: 408–410
Gunther V.W., Richter K.V. Haufigkeitsverteilung von Histokompatibilitatsantigenen (HLA) bei dermatologischen Erkrankungen. Dermatol Monatsschr 1975; 161: 402–404
Retornaz G., Betuel H., Ortonne J.P., et al. HLA antigens and vitiligo. Br J Dermatol 1976; 95: 173–175
Foley L.M., Lowe N.J., Misheloff E., et al. Association of HLA-DR4 with vitiligo. J Am Acad Dermatol 1983; 8: 39–40
Metzker A., Zamir R., Gazit E., et al. Vitiligo and the HLA system. Dermatologica 1980; 160: 100–105
Venneker G.T., de Waal L.P., Westerhof W., et al. HLA associations in vitiligo patients in the Dutch population. Dis Markers 1993; 11: 187–190
Orecchia G., Perfetti L., Malagoli P., et al. Vitiligo is associated with a significant increase in HLA A30, CW6, DQW3 and a decrease in C4AQO in Northern Italian patients. Dermatology 1992; 185: 123–127
Lorini R., Orecchia G., Martinetti M., et al. Autoimmunity in vitiligo: Relationship with HLA, Gm and Km polymorphisms. Autoimmunity 1992; 11: 255–260
Schallreuter K.U., Levenig C., Kuhnl P., et al. Histocompatibility antigens in vitiligo: Hamburg study on 102 patients from northern Germany. Dermatology 1993; 187: 186–192
Bystryn J.C. Serum antibodies in vitiligo patients. Clin Dermatol 1988; 7: 136–145
Grimes P.E., Halder R., Jones C., et al. Autoantibodies and their clinical significance in a black vitiligo population. Arch Dermatol 1983; 119: 300–303
Betterle C., Caretto A., De Zio A., et al. Incidence and significance of organ-specific auto-immune disorders (clinical, latent or only autoantibodies) in patients with vitiligo. Dermatologica 1985; 171: 419–423
Cui J., Arita Y., Bystryn J.C. Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol 1993; 100: 812–815
Cui J., Arita Y., Bystryn J.C. Characterization of vitiligo antigens. Pigment Cell Res 1995; 8: 53–59
Naughton G.K., Reggiardo M.D., Bystryn J.C. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986; 15: 978–981
Harning R., Cui J., Bystryn J.C. Relationship between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991; 97: 1078–1080
Song Y.H., Connor E., Li Y., et al. The role of tyrosinase in autoimmune vitiligo. Lancet 1994; 344: 1049–1052
Baharav E., Merimski O., Shoenfeld Y., et al. Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 1996; 105: 84–88
Kemp E.H., Gawkrodger D.J., MacNeil S., et al. Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol 1997; 109: 69–73
Kemp E.H., Gawkrodger D.J., Watson P.F., et al. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase related protein-2 (TRP-2). Clin Exp Immunol 1997; 109: 495–500
Kemp E.H., Waterman E.A., Gawkrodger D.J., et al. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol 1998; 139: 798–805
Xie Z., Chen D., Jiao D., et al. Vitiligo antibodies are not directed to tyrosinase. Arch Dermatol 1999; 135: 417–422
Al Badri A.M.T., Foulis A.K., Todd P.M., et al. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J Pathol 1993; 169: 203–206
Al Badri A.M.T., Todd P.M., Garioch J.J., et al. An immunohistochemical study of cutaneous lymphocytes in vitiligo. J Pathol 1993; 170: 149–155
Le Poole C.I., van den Wijngaard R.M.J.G.J., Westerhof W., et al. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearence. Am J Pathol 1996; 148: 1219–1228
Ogg G.S., Dunbar P.R., Romero P., et al. High frequency of skin-homing melanocyte specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998; 188: 1203–1208
Soubiran P., Benzaken S., Bellet C., et al. Vitiligo peripheral T-subset imbalance as defined by monoclonal antibodies. Br J Dermatol 1985; 113: 124–127
Grimes P.E., Ghoneum M., Stockton T., et al. T-cell profile in vitiligo. J Am Acad Dermatol 1986; 14: 196–201
Halder R.M., Walters C.S., Johnson B.A., et al. Aberrations in T lymphocytes and natural killer cells in vitiligo: a flow cytometric study. J Am Acad Dermatol 1986; 14: 733–737
d’Amelio R, Frati C., Fattorossi A., et al. Peripheral T-cell subset imbalance in patients with vitiligo and in their apparently healthy first degree relatives. Ann Allerg 1990; 65: 143–145
Mozzanica N., Frigerio U., Finzi A.F., et al. T cell subpopulations in vitiligo: a chronobiologic study. J Am Acad Dermatol 1990; 22: 223–230
Baumer F.E., Frisch W., Milbradt R., et al. Erhohte Expression des OKM5-Antigens auf Blutmonozyten bei Vitiligo. Z Hautkr 1990; 65: 914–919
Abdel Naser M.B., Ludwig W.D. Nonsegmental vitiligo: decrease of the CD45RA+ T-cell subset and evidence for peripheral T-cell activation. Int J Dermatol 1992; 31: 321–326
Mahmoud F., Abul H., Al Saleh Q., et al. Peripheral T-cell activation in non-segmental vitiligo. J Dermatol 1998; 25: 637–640
Orecchia G. Trivino M. Increased natural killer cells in the active phase of vitiligo. Ann Ital Derm Clin Sper 1999; 53: 1–4
Nordlund J.J. The significance of depigmentation. Pigment Cell Res 1992; 2 Suppl.: 237–241
Koga M., Tango T. Clinical features and course of type A and type B vitiligo Br J Dermatol 1988; 118: 223–228
Westerhof W., Bolhaar B., Menke H.E., et al. Resultaten van een enquête onder vitiligo patienten. Ned Tijdschr Dermatol Venereol 1996; 6: 100–105
Lerner A.B., Snell R.S., Chanco-Turner M.L., et al. Vitiligo and sympathectomy. The effect of sympathectomy and alpha-melanocyte stimulating hormone. Arch Dermatol 1966; 94: 269–278
Nelhaus G. Acquired unilateral vitiligo and poliosis of the head and subacute encephalitis with partial recovery. Neurology 1970; 20: 965–974
Arnozan L. Vitiligo avec troubles nerveux sensitifs et sympathetiques: l’origine sympathethique du vitiligo. Bull Soc Fr Dermatol Syphiligr 1992; 29: 338–342
Breatnach A.S., Bor S., Wyllie L.M.A. Electron microscopy of peripheral nerve terminals and marginal melanocytes in vitiligo. J Invest Dermatol 1966; 47: 125–140
Al’Abadie M., Warren M.A., Bleehen S.S., et al. Morphologic observations on the dermal nerves in vitiligo: an ultrastructural study. J Invest Dermatol 1995; 34: 837–840
Liu P.Y., Bondesson L., Lontz W., et al. The occurence of cutaneous nerve endings and neuropeptides in vitiligo vulgaris: a case-control study. Arch Dermatol Res 1996; 288: 670–675
Al’Abadie M.S., Senior H.J., Bleehen S.S., et al. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994; 131: 160–165
Mozzanica N., Villa M.L., Foppa S., et al. Plasma a-melanocyte-stimulating hormone, ß-endorphin, met-enkephalin, and natural killer cell activity in vitiligo. J Am Acad Dermatol 1992; 26: 693–700
Katsambas A.D., Schulpis K.H., Antoniou Ch., et al. ß-endorphin serum levels in patients with vitiligo. J Eur Acad Dermatol 1994; 3: 22–26
Hara M., Toyoda M., Yaar M. Innervation of melanocytes in human skin. J Exp Med 1996; 184: 1385–1395
Iyengar B., Misra R.S. Neural differentation of melanocytes in vitiliginous skin. Acta Anat (Basel) 1988; 133: 62–65
Iyengar B. Modulation of melanocyte activity by acetylcholine. Acat Anat (Basel) 1989; 136: 139–140
Kaur A., Sarin R.C. Studies of neurotropic influences in vitiligo. Indian J Dermatol 1988; 33: 33–36
Merello M., Nogues M., Leiguarda R., et al. Abnormal sympathetic skin response in patients with autoimmune vitiligo and primary autoimmune hypothyroidism. J Neurol 1993; 240: 72–74
Le Poole I.C., van den Wijngaard R.M.J.G.J., Smit N.P., et al. Catechol-o-methyltransferase in vitiligo. Arch Dermatol Res 1994; 286: 81–86
Morrone A., Picardo M., de Luca C., et al. Catecholamines and vitiligo. Pigment Cell Res 1992; 5: 58–62
Lerner A.B. On the etiology of vitiligo and gray hair. Am J Med 1971; 51: 141–147
Cummings M.P., Nordlund J.J. Chemical leukoderma; fact or fancy. Am J Contact Dermatitis 1995; 6: 122–127
Nordlund J.J., Ortonne J.P. Vitiligo and depigmentation. In: Weston W.L., Mackie R.M., Provost T.T., editors. Current problems in dermatology. Mosby Year Book Inc. St. Louis, 1992: 3–30
Slominski A., Paus A.R., Bomirski A. Hypothesis; possible role for the melatonin receptor in vitiligo [discussion paper]. J Royal Soc Med 1989; 82: 539–541
Schallreuter K.U., Wood J.M., Ziegler I., et al. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochem Biophys Acta 1994; 1226: 181–192
Schallreuter K.U., Wood J.M., Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991; 97: 1081–1085
Schallreuter K.U., Wood J.M., Lemke K.R., et al. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case on 33 patients. Dermatology 1995; 190: 223–229
Maresca V., Roccella M., Roccella F., et al. Increased sensitivity to peroxidative agents as possible pathogenetic factor of melanocyte damage in vitiligo. J Invest Dermatol 1997; 109: 310–313
Passi S., Grandinetti M., Maggio F., et al. Epidermal oxidative stress in vitiligo. Pigment Cell Res 1998; 11: 81–85
Puri N., Majumder M., Ramaiah A. In vitro growth characteristics of melanocytes obtained from adult normal and vitiligo subjects. J Invest Dermatol 1987; 88: 434–438
Ramaiah A., Puri N., Majumder M. Etiology of vitiligo. A new hypothesis. Acta Derm Venereol (Stockh) 1989; 69: 323–367
Le Poole I.C., Das P.K., van den Wijngaard R.M., et al. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993; 2: 145–153
Westerhof W., Nieuweboer-Krobotova L. Treatment of vitiligo with narrowband UV-B versus topical psoralen plus UV-A. Arch Dermatol 1997; 133: 1525–1528
Njoo M.D., Bos J.D., Westerhof W. Treatment of generalized vitiligo in children with narrowband (TL-01) UV-B radiation therapy. J Am Acad Dermatol 2000; 42: 245–253
British Photodermatology Group An appraisal of narrowband (TL-01) UV-B phototherapy. British Photodermatology Group Workshop Report (April 1996). Br J Dermatol 1997; 137: 327–330
Grimes P.E. Psoralen photochemotherapy for vitiligo. Clin Dermatol 1997; 15: 921–926
Drake L.A., Ceilley R.I., Dorner W., et al. Guidelines of care for phototherapy and photochemotherapy. J Am Acad Dermatol 1994; 31: 643–653
Gupta A.K., Anderson T.F. Psoralen photochemotherapy. J Am Acad Dermatol 1987; 17: 703–734
Ortonne J.P., MacDonald D.M., Micoud A., et al. PUVA-induced repigmentation of vitiligo: a histochemical (split-DOPA) and ultrastructural study. Br J Dermatol 1979; 101: 1–12
Ortonne J.P., Shmitt D., Thivolet J. PUVA-induced repigmentation of vitiligo: scanning elctron microscopy of hair follicles. J Invest Dermatol 1980; 74: 40–42.
Cui J., Wang G.C. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol 1991; 97: 410–416
Horikawa T., Norris D.A., Johnson T.W., et al. DOPA-negative melanocytes in the outer root sheath of human hair follicles express premelanosomal antigens but not a melanosomal antigen or the melanosome associated glycoproteins tyrosinase TRP-1 and TRP-2. J Invest Dermatol 1996; 106: 28–35
Norris D.A., Horikawa T., Morelli J.G. Melanocyte destruction and repopulation in vitiligo. Pigment Cell Res 1994; 7: 193–203
Abdel Naser M.B., Hann S.K., Bystryn J.C. Oral psoralen with UV-A therapy releases circulating growth factors that stimulate cell proliferation. Arch Dermatol 1997; 133: 1530–1533
Kao C., Yu H. Comparison of the effect of 8-methoxypsoralen (8-MOP) plus UVA (PUVA) on human melanocytes in vitiligo vulgaris and in vitro. J Invest Dermatol 1992; 98: 734–740
Hann S.K., Shin H.K., Song M.S., et al. The effect of systemic PUVA on the proliferation of melanocytes and the titer of anti-pigment cell autoantibodies in patients with vitiligo. Korean J Dermatol 1997; 35: 57–70
Köster W., Wiskemann A. Phototherapy with UV-B in vitiligo. Zeitschr Hautkrank 1990; 65: 1022–1024
Njoo M.D., Bossuyt P.M.M., Westerhof W. Management of vitiligo. Results of a questionnaire among dermatologists in The Netherlands. Int J Dermatol 1999; 38: 866–872
Stern R.S., Lange R., and Members of the Photochemotherapy Follow-up Study. Nonmelanoma skin cancer occuring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988; 91: 120–124
Stern R.S., Nichols K.T., Vakeva L.H. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Eng J Med 1997; 336: 1041–1045
Nordlund J.J., Ortonne J.P. Vitiligo vulgaris. In: Nordlund J.J., Boissy R.E., Hearing V.J., et al., editors. The pigmentary system. Physiology and pathophysiology. New York: Oxford University Press, 1998: 513–514
Lindelof B., Hedblad M.A., Sigurgeirsson B. On the association between vitiligo and malignant melanoma. Acta Derm Venereol (Stockh) 1998; 78: 483–484
Buckley D.A., Rogers S. Multiple keratoses and squamous carcinoma after PUVA treatment of vitiligo. Clin Exp Dermatol 1996; 21: 43–45
Takeda H., Mitsuhashi Y., Kondo S. Multiple squamous cell carcinomas in situ in vitiligo after long-term PUVA therapy. J Am Acad Dermatol 1998; 38: 268–270.
British Photodermatology Group British Photodermatology Group guidelines for PUVA. Br J Dermatol 1994; 130: 246–255
Studniberg H.M., Weller P. PUVA, UV-B, psoriasis and nonmelanoma skin cancers. J Am Acad Dermatol 1993; 29: 1013–1022
Koopmans van Dorp B., Goedhart van Dijjk B., Neering H., et al. Treatment of vitiligo by local application of betamethasone 17-valerate in a dimethyl sulfoxide cream base. Dermatologica 1973; 146: 310–314
Bleehen S.S. The treatment of vitiligo with topical corticosteroids. Light and electronmicroscopic studies. Br J Dermatol 1976; 94 Suppl. 12: 43–50
Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol 1984; 120: 631–635
Kandil E. Treatment of localized vitiligo with intradermal injections of triamcinolonacetonide. Dermatologica 1970; 140: 195–206
Moon T.K., Im S.B., Hann S.K., et al. The effect of small doses of oral corticosteroids in vitiligo patients. Korean J Dermatol 1995; 33: 880–885
Kim S.M., Lee H.S., Hann S.K. The efficacy of low-dose corticosteroids in the treatment of vitiligo. Int J Dermatol 1999; 38: 546–550
Pasricha J.S., Khaitan B.K. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol 1993; 32: 753–757
Kanwar A.J., Dhar S., Dawn G. Oral minipulse therapy in vitiligo. Dermatologica 1995; 190: 251–252
Xunquan L., Changgeng S., Peiying J., et al. Treatment of localized vitiligo with Ulobetasol cream. Int J Dermatol 1990; 29: 295–297
Hann S.K., Kim H.I., Im S., et al. The change of melanocyte cytotoxicity after systemic steroid treatment in vitiligo patients. J Dermatol Sci 1993; 6: 201–205
Hann S.K., Chen D., Bystryn J.C. Systemic steroids suppress antimelanocyte antibodies in vitiligo. J Cut Med Surg 1997; 14: 193–195
Falabella R., Arrunategui A., Barona M.I., et al. The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation. J Am Acad Dermatol 1995; 32: 228–232
Westerhof W., Boersma B. The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation. J Am Acad Dermatol 1995; 33: 1061–1062
Boersma B.R., Westerhof W., Bos J.D. Repigmentation in vitiligo vulgaris by autologous minigrafting: results in nineteen patients. J Am Acad Dermatol 1995; 33: 990–995
Njoo M.D., Nieuweboer-Krobotova L., Westerhof W. Repigmentation of leukodermic defects in piebaldism by dermabrasion and thin split-thickness skin grafting in combination with minigrafting. Br J Dermatol 1998: 139; 829–833
Falabella R. Epidermal grafting. An original technique and its application in achromic and granulating areas. Arch Dermatol 1971; 104: 592–600
Lerner A.B., Halaban R., Klaus S.N., et al. Transplantation of human melanocytes. J Invest Dermatol 1987; 89: 219–224
Olsson M.J., Juhlin L. Transplantation of melanocytes in vitiligo. Br J Dermatol 1995; 132: 587–591
Falabella R., Escobar C., Borrero I. Transplantation of in vitro cultured epidermis bearing melanocytes for repigmenting vitiligo. J Am Acad Dermatol 1989; 21: 257–264
Plott R.T., Brysk M.M., Newton R.C., et al. A surgical treatment for vitiligo: Autologous cultured-epithelial grafts. J Dermatol Surg Oncol 1989; 15: 1161–1166.
Gauthier Y., Surleve-Bazeille J.E. Autologous grafting with noncultured melanocytes: a simplified method for treatment of depigmented lesions. J Am Acad Dermatol 1992; 26: 191–194
Olsson M.J., Juhlin L. Leucoderma treated by transplantation of a basal layer enriched suspension. Br J Dermatol 1998; 138: 644–648
Nordlund J.J. Vitiligo. In: Thiers B.H., Dobson R.L., editors. Pathogenesis of skin disease. New York: Churchill Livingstone, 1986: 99–127
Mosher D.B., Parrish J.A., Fitzpatrick T.B. Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature. Br J Dermatol 1977; 97: 669–679
Njoo M.D., Vodegel R.M., Westerhof W. Depigmentation therapy in vitiligo universalis with 4-methoxyphenol and the Q-switched ruby laser. J Am Acad Dermatol 2000; 42: 760–769
Nordlund J.J., Forget B., Kirkwood J., et al. Dermatitis produced by applications of monobenzone in patients with active vitiligo. Arch Dermatol 1985; 121: 1141–1144
Hedges T.R., Kenyon K.R., Hanninen L.A., et al. Corneal and conjunctival effects of monobenzone in patients with vitiligo. Arch Ophthalmol 1983; 101: 64–68
Snider R.I., Thiers B.H. Exogenous ochronosis. J Am Acad Dermatol 1993; 28: 662–664
Thissen M. Westerhof W. Laser treatment for further depigmentation in vitiligo. Int J Dermatol 1997; 36: 386–388
Westerhof W., Nieuweboer-Krobotova L., Mulder P.G.H., et al. Left-right comparison study of the combination fluticasone propionate and UV-A vs either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 1999; 135: 1061–1066
Lotti T., Rebora A. Vitiligo therapy: the Ratok terapia. Clinical assessment of focused microphotostimulation treatment by means of the Ratokderm equipment and method during five years (1990–1995). Vitiligo Special 1998
Cao C.M. Melagenine: a Cuban product. A new and effective drug for the treatment of vitiligo. Series of National Reports, Republic of Cuba, Havana, 1986
Souto M.G., Manhaes, Milhomens C.H., et al. Estudo comparativo entre melagenina e placebo no tratamento do vitiligo. An Bras Dermatol Rio de Janeiro 1997; 72: 237–239
Nordlund J.J., Halder R. Melagenina. An analysis of published and other available data. Dermatologica 1990; 181: 1–4
Hann S.K., Im S., Park Y.K., et al. Repigmentation of leukotrichia by epidermal grafting and systemic psoralen plus UVA. Arch Dermatol 1992; 128: 998–999
Na G.Y., Seo S.K., Choi S.K. Single hair grafting for the treatment of vitiligo. J Am Acad Dermatol 1998; 38; 580–584
Njoo M.D., Spuls Ph. I., Bos J.D., t al. Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol 1998; 134: 1532–1540
Njoo M.D., Westerhof W., Bos J.D., et al. A systematic review of autologous transplantation methods in vitiligo. Arch Dermatol 1998; 134: 1543–1549
Njoo M.D., Westerhof W., Bos J.D., et al. The development of guidelines for the treatment of vitiligo. Arch Dermatol 1999; 135: 1514–1521
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Njoo, M.D., Westerhof, W. Vitiligo. Am J Clin Dermatol 2, 167–181 (2001). https://doi.org/10.2165/00128071-200102030-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200102030-00006